The Market Reports

Synopsis

The global market for Hepatocyte Growth Factor was estimated to be worth US$ 75.8 million in 2024 and is forecast to a readjusted size of US$ 426 million by 2031 with a CAGR of 28.0% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Hepatocyte Growth Factor cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration, and in wound healing.

Current drug development targeting the HGF pathway is bifurcated into neuroregeneration and oncology tracks, with clinical pipelines focused on indications such as diabetic neuropathy, ALS, spinal cord injury, stroke, and various solid tumors including NSCLC and gastric cancer. Globally, companies like Helixmith, AnGes MG, and Kringle Pharma are advancing gene therapies and recombinant proteins for neurological indications.

Athira Pharma and AVEO are developing small molecules and antibodies targeting the HGF/c-Met axis, while Exelixis and Molecular Partners pursue broader oncology strategies via multi-target approaches. Beijing Northland represents China’s early-stage involvement in this area. The landscape is marked by diversified modalities and parallel development paths, with several assets reaching late-stage trials or conditional approvals, indicating strong commercialization potential in regenerative medicine and rare diseases.

This report aims to provide a comprehensive presentation of the global market for Hepatocyte Growth Factor, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Hepatocyte Growth Factor by region & country, by Type, and by Application.

The Hepatocyte Growth Factor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatocyte Growth Factor.

Market Segmentation

By Company

• Helixsmith
• Exelixis
• AnGes MG
• Athira Pharma
• AVEO Pharmaceuticals
• Molecular Partners
• Kringle Pharma
• Beijing Northland

Segment by Type

• Phase III (Ongoing)
• Phase II (Approved)
• Phase II (Ongoing)
• Phase 1
• Preclinical
• Approved / Marketed

Segment by Application

• Oncology
• Cardiovascular
• Central Nervous System
• Hematological Disorders
• Others

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.